• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Exicure Inc.

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XCUR alert in real time by email
    SC 13D 1 d882574dsc13d.htm SC 13D SC 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Exicure, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    30205M309

    (CUSIP Number)

    Andy Yoo

    Chief Executive Officer

    HiTron Systems Inc.

    99-13 Masan-Gil, Miyang-Myeon

    Anseong-si, Gyeonggi-do

    Korea 17601

    +82-106-220-2280

    with a copy to

    Jeongseok Jay Yu, Esq.

    Daniel S. Clevenger, Esq.

    Foley Hoag LLP

    Seaport West

    155 Seaport Boulevard

    Boston, MA 02210

    617-832-1000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    November 21, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 30205M309    13D    Page 1 of 7 Pages

     

     1.    

     Names of Reporting Persons.

     

     HiTron Systems Inc.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Source of Funds (See Instructions)

     

     OO

     5.  

     Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     6.  

     Citizenship or Place of Organization

     

     Republic of Korea

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

        7.     

     Sole Voting Power

     

     433,333

        8.   

     Shared Voting Power

     

     0

        9.   

     Sole Dispositive Power

     

     433,333

       10.   

     Shared Dispositive Power

     

     0

    11.    

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     433,333

    12.  

     Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

     ☐

    13.  

     Percent of Class Represented by Amount in Row (11)

     

     16.6%

    14.  

     Type of Reporting Person (See Instructions)

     

     CO


    CUSIP No. 30205M309       Page 2 of 7 Pages

     

    Item 1. Security and Issuer.

    This statement on Schedule 13D (this “Statement”) relates to the shares of common stock, par value $0.0001 per share (the “Common Stock”), of Exicure, Inc., a Delaware corporation (the “Issuer”). The Issuer’s principal executive offices are located at 2430 N. Halsted Street, Chicago, IL 60614.

    Item 2. Identity and Background.

    (a)-(c), (f) This Statement is being filed by HiTron Systems Inc., a South Korea corporation (the “Reporting Person”). The business address of the Reporting Person is 99-13 Masan-Gil, Miyang-Myeon, Anseong-si, Gyeonggi-do, Korea 17601. The principal business of the Reporting Person is designing, developing, and manufacturing advanced security and surveillance solutions. Its products include AI-enabled security cameras, recording solutions, and cybersecurity-compliant systems.

    The name, business address, present principal occupation or employment and citizenship of each director and executive officer of the Reporting Person is set forth on Schedule A.

    (d) During the last five years, neither the Reporting Person nor, to the best knowledge of the Reporting Person, any of the persons listed on Schedule A, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e) During the last five years, neither the Reporting Person nor, to the best knowledge of the Reporting Person, any of the persons listed on Schedule A, has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order (1) enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or (2) finding any violation with respect to such laws.

    Item 3. Source and Amount of Funds.

    On November 21, 2024, the Reporting Person purchased 433,333 shares of Common Stock (the “Shares”) at a purchase price of $3.00 per share, or approximately $1,300,000 in the aggregate, in a private placement pursuant to a Common Stock Purchase Agreement dated November 6, 2024 and signed on November 12, 2024 (the “Initial Purchase Agreement” and, such purchase, the “Initial Stock Purchase”). The Initial Stock Purchase was subject to certain closing conditions, including completion of overseas investment reporting obligations under the Korean Foreign Exchange Transactions Act and obtaining all regulatory approvals in accordance with Korean laws (the “Korean Regulatory Approval”). The Initial Stock Purchase was funded through the issuance of an aggregate of KRW 10,000,000,000 in convertible bonds of the Reporting Person to Widwin Investment Fund No. 72 (the “Convertible Bonds”), issued pursuant to a Convertible Bond Agreement dated September 6, 2024 (the “Convertible Bond Agreement”). The Convertible Bonds accrue interest at a rate of 2.9% per annum and mature on September 19, 2027. The Convertible Bonds are subject to early repayment at the option of the holder beginning September 19, 2025, and are convertible into shares of common stock of the Reporting Person at any time from September 19, 2025, through August 19, 2027 at a rate of 100% of the electronic registration amount claimed for exercise of conversion claim divided by KRW 901, as may be subject to adjustment in the case of specific events described in the Convertible Bonds.


    CUSIP No. 30205M309       Page 3 of 7 Pages

     

    The foregoing description of the Convertible Bonds does not purport to be complete and is qualified in its entirety by reference to the full text of the Convertible Bond Agreement, an English translation of which is incorporated by reference as an exhibit to this Statement.

    Item 4. Purpose of Transaction.

    The information set forth under Item 3 is incorporated herein by reference into this Item 4.

    In addition to the Initial Purchase Agreement, on November 13, 2024, the Reporting Person entered into a second Common Stock Purchase Agreement with the Issuer (the “Second Purchase Agreement” and, together with the Initial Purchase Agreement, the “Purchase Agreements”), pursuant to which the Reporting Person agreed, subject to the satisfaction of certain conditions, to purchase from the Issuer an additional 2,900,000 shares of Common Stock at a purchase price of $3.00 per share, or $8,700,000 in the aggregate (the “Second Stock Purchase” and, together with the “Initial Stock Purchase,” the “Stock Purchases”). Among other conditions, the closing of the Second Stock Purchase is subject to approval of the stockholders of the Issuer and Korean Regulatory Approval.

    The Shares reported on this Statement were acquired for investment purposes, and the Initial Purchase Agreement provides that the Issuer will use the proceeds from the Initial Stock Purchase for purposes of acquiring GPCR Therapeutics USA, Inc. The Reporting Person expects to evaluate on an ongoing basis the Issuer’s financial condition and prospects and their respective interests in, and intentions with respect to, the Issuer and their respective investments in the securities of the Issuer, which review may be based on various factors, including the Issuer’s business and financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer’s securities in particular, as well as other developments and other investment opportunities. Accordingly, the Reporting Person reserves the right to change its intentions, as it deems appropriate. In particular, the Reporting Person may at any time and from time to time, subject to compliance with the terms of the Purchase Agreements, including the lock-up restrictions described below, in the open market, in privately negotiated transactions or otherwise, increase its holdings in the Issuer or dispose of all or a portion of the securities of the Issuer that the Reporting Person now owns, expects to acquire in the Second Stock Purchase, or otherwise may hereafter acquire, including sales pursuant to the exercise of the registration rights provided for in the Purchase Agreements. In addition, the Reporting Person may engage in discussions with management and members of the board of directors of the Issuer (the “Issuer Board”) regarding the Issuer, including, but not limited to, the Issuer’s business and financial condition, results of operations and prospects. The Reporting Person may take positions with respect to and seek to influence the Issuer regarding the matters discussed above. Such suggestions or positions may include one or more plans or proposals that relate to or would result in any of the actions required to be reported herein.


    CUSIP No. 30205M309       Page 4 of 7 Pages

     

    The Reporting Person may have the ability, as a result of its holding the Shares, to influence or determine the vote with respect to significant matters involving the Issuer, including the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, and such ability to influence or determine the vote with respect to significant matters involving the Issuer will increase if the Second Stock Purchase closes. In addition, pursuant to the Initial Purchase Agreement, on November 21, 2024, the Reporting Person nominated, and the Issuer Board appointed, each of Andy Yoo, the Chief Executive Officer of the Reporting Person, and Seung Ik Baik, to the Issuer Board, and the Issuer appointed Mr. Yoo to serve as the Issuer’s Chief Restructuring Officer. In the event that the Second Stock Purchase closes, pursuant to the Second Purchase Agreement, the Reporting Person will have the right to nominate, and the Issuer has agreed to take all necessary actions to appoint, a number of directors substantially equivalent to the Reporting Person’s proportional equity ownership of shares of Common Stock of the Issuer. Any of these individuals may, individually or together, have influence over the corporate activities of the Issuer, including activities which may relate to items described in paragraphs (a) through (j) of Item 4 of Schedule 13D. Certain plans or proposals may from time to time be discussed or considered by the directors or executive officers of the Issuer, in each of their fiduciary capacities as a director or executive officer of the Issuer.

    Pursuant to the Purchase Agreements, the Reporting Person is subject to a 90-day lock-up period with respect to shares of Common Stock commencing from the date of closing of the Initial Stock Purchase and the Second Stock Purchase, as applicable.

    Except as set forth above in this Item 4, the Reporting Persons have no present plans or proposals that relate to, or that would result in, any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D under the Act. The Reporting Persons do, however, reserve the right in the future to adopt such plans or proposals subject to compliance with applicable regulatory requirements.

    Item 5. Interest in Securities of the Issuer.

    The information set forth under Item 3 and the cover page of this Statement is incorporated herein by reference into this Item 5.

    The percentage of beneficial ownership reported in this Item 5, and on the Reporting Person’s cover page to this Statement, is based on a total of 2,605,656 shares of Common Stock, which represents the number of shares of Common Stock reported as outstanding on November 7, 2024 in the Quarterly Report on Form 10-Q filed by the Issuer on November 14, 2024, increased by the number of shares of Common Stock issued to the Reporting Person pursuant to the Initial Purchase Agreement. All of the share numbers reported below, and on the Reporting Person’s cover page to this Statement, are as of November 21, 2024 and give effect to the Initial Stock Purchase. The cover page to this Statement is incorporated by reference in its entirety into this Item 5.

    (a) The Reporting Person is the beneficial owner of a total of 433,333 shares of Common Stock, representing approximately 16.6% of the outstanding shares of Common Stock.


    CUSIP No. 30205M309       Page 5 of 7 Pages

     

    (b) The Reporting Person has sole voting and dispositive power over all such shares described in Item 5(a) above.

    (c) Except for the Initial Stock Purchase, the Reporting Person has not effected any transactions in shares of Common Stock during the past 60 days.

    (d) No person other than the Reporting Person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, shares of Common Stock.

    (e) Not applicable.

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    The information set forth under Items 3 and 4 is incorporated herein by reference into this Item 6.

    In connection with the Purchase Agreements, the Reporting Person entered into Registration Rights Agreements with the Issuer (the “Registration Rights Agreements”), pursuant to which the Issuer agreed to register for resale the shares of Common Stock sold to the Reporting Person pursuant to the Purchase Agreements, in each case no later than sixty days following the closing of the applicable Stock Purchase.

    Each of the foregoing descriptions of the Initial Purchase Agreement, the Second Purchase Agreement and the Registration Rights Agreements, as applicable, does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, copies of which are incorporated by reference as exhibits to this Statement.

    Item 7. Material to be Filed as Exhibits.

     

    Exhibit No.

      

    Exhibit

    99.1    Common Stock Purchase Agreement, dated November  6, 2024, by and between Exicure, Inc. and HiTron Systems Inc. (incorporated by reference to Exhibit 10.1 of the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November  14, 2024)
    99.2    Form of Registration Rights Agreement by and between Exicure, Inc. and HiTron Systems Inc. (incorporated by reference to Exhibit 10.2 of the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 14, 2024)


    CUSIP No. 30205M309       Page 6 of 7 Pages

     

    99.3    Common Stock Purchase Agreement, dated November  13, 2024, by and between Exicure, Inc. and HiTron Systems Inc. (incorporated by reference to Exhibit 10.3 of the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November  14, 2024)
    99.4    25th Bearer-type Non-guaranteed Private Placement Convertible Bonds Agreement, dated September 6, 2024 by and between HiTron Systems Inc. and Widwin Investment Fund No. 72.

    * * *


    CUSIP No. 30205M309       Page 7 of 7 Pages

     

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DATE: November 29, 2024
    HiTron Systems Inc.
    By:   /s/ Andy Yoo
    Name: Andy Yoo
    Title: Chief Executive Officer


    Schedule A

    Directors and Officers of HiTron Systems Inc.

     

    Name

      

    Position/Principal Occupation

      

    Business Address

      

    Citizenship

    Andy Yoo    Director and Chief Executive Officer    99-13 Masan-Gil, Miyang-Myeon, Anseong-si, Gyeonggi-do, South Korea    Australia
    Sangwook Song    Director    99-13 Masan-Gil, Miyang-Myeon, Anseong-si, Gyeonggi-do, South Korea    Republic of Korea
    Ji Won Jung    Director    99-13 Masan-Gil, Miyang-Myeon, Anseong-si, Gyeonggi-do, South Korea    Republic of Korea
    Jaesook Lee    Director    99-13 Masan-Gil, Miyang-Myeon, Anseong-si, Gyeonggi-do, South Korea    Republic of Korea
    Get the next $XCUR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XCUR

    DatePrice TargetRatingAnalyst
    12/13/2021$2.25 → $0.40Buy → Neutral
    Chardan Capital Markets
    11/23/2021$7.00 → $2.25Buy
    Chardan Capital
    More analyst ratings

    $XCUR
    SEC Filings

    See more
    • Exicure Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - EXICURE, INC. (0001698530) (Filer)

      6/10/25 4:47:29 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exicure Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - EXICURE, INC. (0001698530) (Filer)

      5/28/25 5:17:59 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by Exicure Inc.

      NT 10-Q - EXICURE, INC. (0001698530) (Filer)

      5/15/25 4:29:41 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XCUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Hitron Systems Inc. bought $8,700,000 worth of shares (2,900,000 units at $3.00), increasing direct ownership by 669% to 3,333,333 units (SEC Form 4)

      4 - EXICURE, INC. (0001698530) (Issuer)

      3/26/25 5:41:19 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Dgp Co., Ltd. bought $711,669 worth of shares (237,223 units at $3.00), increasing direct ownership by 39% to 849,223 units (SEC Form 4)

      4 - EXICURE, INC. (0001698530) (Issuer)

      9/16/24 9:41:12 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XCUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exicure downgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets downgraded Exicure from Buy to Neutral and set a new price target of $0.40 from $2.25 previously

      12/13/21 8:43:28 AM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital reiterated coverage on Exicure with a new price target

      Chardan Capital reiterated coverage of Exicure with a rating of Buy and set a new price target of $2.25 from $7.00 previously

      11/23/21 8:42:55 AM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Exicure with a new price target

      HC Wainwright & Co. reiterated coverage of Exicure with a rating of Buy and set a new price target of $6.00 from $8.00 previously

      5/17/21 7:10:54 AM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XCUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Miller Josh covered exercise/tax liability with 8 shares, decreasing direct ownership by 2% to 325 units (SEC Form 4)

      4 - EXICURE, INC. (0001698530) (Issuer)

      5/23/25 6:19:40 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Hitron Systems Inc. bought $8,700,000 worth of shares (2,900,000 units at $3.00), increasing direct ownership by 669% to 3,333,333 units (SEC Form 4)

      4 - EXICURE, INC. (0001698530) (Issuer)

      3/26/25 5:41:19 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Kang Min Woo

      3 - EXICURE, INC. (0001698530) (Issuer)

      3/24/25 8:34:19 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XCUR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

      Exicure, Inc. ("Exicure" or the "Company") (NASDAQ:XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on May 21, 2025 notifying the Company that, as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q by May 20, 2025 for the quarterly period ended March 31, 2025 (the "Form 10-Q"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission (the "SEC"). Under Nasdaq's listing rules, Exicure has 60 calendar days to submit a plan to regain compliance. If the plan

      5/28/25 4:58:00 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

      Topline results expected H2 2025 Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed patient enrollment in its ongoing Phase 2 clinical trial (NCT05561751) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant (ASCT). The randomized, open-label, multicenter study is designed to assess whether GPC-100, a small molecule CXCR4 antagonist, can improve CD34+ hematopoietic stem cell mobilization from the bone marrow into the peripheral blood, where they can be collected via leukaph

      5/5/25 8:00:00 AM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

      Exicure, Inc. (NASDAQ:XCUR) today announced that GPCR Therapeutics USA, a subsidiary of Exicure Inc., has dosed the 19th patient in its ongoing Phase 2 clinical trial evaluating GPC-100 (burixafor), a small molecule CXCR4 inhibitor, for the mobilization of stem cells in multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT) (NCT05561751). The study is an open-label, multi-center trial evaluating the safety and efficacy of GPC-100 and propranolol in combination with G-CSF. Data from an interim analysis of 10 patients were previously presented at the 2024 American Society of Hematology (ASH) Annual Meeting. Preliminary results are encouraging, with 100% of patients

      4/14/25 6:11:00 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XCUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Exicure Inc.

      SC 13D - EXICURE, INC. (0001698530) (Subject)

      11/29/24 5:51:28 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Exicure Inc.

      SC 13D/A - EXICURE, INC. (0001698530) (Subject)

      9/16/24 9:38:56 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Exicure Inc.

      SC 13D/A - EXICURE, INC. (0001698530) (Subject)

      8/5/24 6:22:26 PM ET
      $XCUR
      Biotechnology: Pharmaceutical Preparations
      Health Care